Search

Product: Palopegteriparatide

Palopegteriparatide Enhances Work Functioning and Productivity in Employed Adults With Chronic Hypoparathyroidism: 156-Week Results From the PaTHway Trial

Palopegteriparatide Enhances Work Functioning and Productivity in Employed Adults With Chronic Hypoparathyroidism: 156-Week Results From the PaTHway Trial

medaffairinfus | July 21, 2026

Read More
Palopegteriparatide Treatment in Adults With Hypoparathyroidism: Final Results of the Phase 3 PaTHway Trial

Palopegteriparatide Treatment in Adults With Hypoparathyroidism: Final Results of the Phase 3 PaTHway Trial

medaffairinfus | July 21, 2026

Read More
Five-Year Data Report From the Phase 2 PaTH Forward Trial of Palopegteriparatide for Adults With Hypoparathyroidism

Five-Year Data Report From the Phase 2 PaTH Forward Trial of Palopegteriparatide for Adults With Hypoparathyroidism

medaffairinfus | July 21, 2026

Read More
Sustained Improvement in Renal Function With Palopegteriparatide in Adults With Chronic Hypoparathyroidism: Three-Year Results From the PaTH Forward and PaTHway Trials

Sustained Improvement in Renal Function With Palopegteriparatide in Adults With Chronic Hypoparathyroidism: Three-Year Results From the PaTH Forward and PaTHway Trials

medaffairinfus | April 17, 2026

Read More

Palopegteriparatide for Adults With Chronic Hypoparathyroidism: Skeletal Dynamics Through 3 Years of the Phase 2 PaTH Forward Trial

medaffairinfus | March 13, 2026

Read More

Patient-Reported Outcomes in Palopegteriparatide-Treated Adults With Hypoparathyroidism: PaTH Forward Trial Extension

medaffairinfus | March 13, 2026

Read More

Early U.S. Real-World Treatment Patterns and Outcomes in Palopegteriparatide Treatment for Patients With Hypoparathyroidism

medaffairinfus | December 16, 2025

Read More

Palopegteriparatide Treatment Improves Renal Function in Adults With Chronic Hypoparathyroidism: 1-Year Results From the Phase 3 PaTHway Trial

medaffairinfus | December 16, 2025

Read More

Efficacy and Safety of TransCon PTH in Adults With Hypoparathyroidism: 52-Week Results From the Phase 3 PaTHway Trial

medaffairinfus | December 16, 2025

Read More

Efficacy and Safety of Parathyroid Hormone Replacement With TransCon PTH in Hypoparathyroidism: 26-Week Results From the Phase 3 PaTHway Trial

medaffairinfus | December 16, 2025

Read More